Cilostazol regulates the expressions of endothelin‑1 and endothelial nitric oxide synthase via activation of the p38 MAPK signaling pathway in HUVECs

Xue,Ying; Li,Xiaoye; Wang,Zi; Lv,Qianzhou

doi:10.3892/br.2022.1560

Cilostazol regulates the expressions of endothelin‑1 and endothelial nitric oxide synthase via activation of the p38 MAPK signaling pathway in HUVECs

Authors:
- Ying Xue
- Xiaoye Li
- Zi Wang
- Qianzhou Lv
View Affiliations

Affiliations: Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: July 29, 2022 https://doi.org/10.3892/br.2022.1560
Article Number: 77

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cilostazol is a selective inhibitor of phosphodiesterase type III that inhibits platelet aggregation. The beneficial effects of cilostazol have been attributed not only to its antiplatelet functions but also to its actions on the endothelium. Whether cilostazol regulates endothelin‑1 (ET‑1) and endothelial nitric oxide synthase (eNOS) through mitogen‑activated protein kinase (MAPK) remains undetermined. The aim of this study was to investigate the effects of cilostazol on ET‑1 and eNOS expression in HUVECs, and to assess its relationship with MAPK activity. HUVECs were cultured in vitro, stimulated with TNF‑α, and pretreated with different concentrations of cilostazol. ET‑1 and eNOS levels in the supernatant were detected by ELISA. RT‑qPCR was performed to detect the mRNA expression levels of ET‑1 and eNOS. The phosphorylation levels of p38/MAPK and protein expression levels of ET‑1 and eNOS were assessed using western blotting. A P38 inhibitor, SB203580, was utilized to further validate the involvement of p38/MAPK in the regulation. Expression of ET‑1, which was upregulated by TNF‑α, was significantly suppressed by cilostazol in a dose‑dependent manner, meanwhile, with as the cilostazol concentration was increased, the expression of eNOS increased as well. In addition, cilostazol also decreased phosphorylation of p38, which was upregulated by TNF‑α. The observed upregulation of eNOS and ET‑1 levels were completely abolished upon p38 inhibitor treatment, indicating the involvement of the p38/MAPK pathway in cilostazol‑induced regulation of eNOS and ET‑1 in HUVECs. The results indicated that cilostazol regulates ET‑1 and eNOS production by suppressing the p38/MAPK signaling pathway in TNF‑α‑stimulated HUVECs, and this may contribute to the protective effects of cilostazol on the endothelium.

View Figures

View References

1	Reriani MK, Flammer AJ, Jama A, Lerman LO and Lerman A: Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome. Circ J. 76:778–783. 2012.PubMed/NCBI View Article : Google Scholar
2	el-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Kerensky RA, Conti CR and Pepine CJ: Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Endothelial function revisited. Circulation. 89:45–51. 1994.PubMed/NCBI View Article : Google Scholar
3	Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Yu-An Ding P and Lin SJ: Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. Int J Cardiol. 114:152–158. 2007.PubMed/NCBI View Article : Google Scholar
4	Martin BJ and Anderson TJ: Risk prediction in cardiovascular disease: The prognostic significance of endothelial dysfunction. Can J Cardiol. 25 (Suppl A):15A–20A. 2009.PubMed/NCBI View Article : Google Scholar
5	Li H, Horke S and Förstermann U: Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 237:208–219. 2014.PubMed/NCBI View Article : Google Scholar
6	Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N and Stefanadis C: The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 10:4–18. 2012.PubMed/NCBI View Article : Google Scholar
7	Sogo N, Magid KS, Shaw CA, Webb DJ and Megson IL: Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun. 279:412–419. 2000.PubMed/NCBI View Article : Google Scholar
8	Miyauchi T and Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 61:391–415. 1999.PubMed/NCBI View Article : Google Scholar
9	Lüscher TF and Barton M: Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 102:2434–2440. 2000.PubMed/NCBI View Article : Google Scholar
10	Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 340:115–126. 1999.PubMed/NCBI View Article : Google Scholar
11	Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G and Nishigaki I: The vascular endothelium and human diseases. Int J Biol Sci. 9:1057–1069. 2013.PubMed/NCBI View Article : Google Scholar
12	Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, Yoshitake M, Kambayashi J and Liu Y: Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol. 34:497–504. 1999.PubMed/NCBI View Article : Google Scholar
13	Guerra E, Byrne RA and Kastrati A: Pharmacological inhibition of coronary restenosis: Systemic and local approaches. Expert Opin Pharmacother. 15:2155–2171. 2014.PubMed/NCBI View Article : Google Scholar
14	Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Kim DK, Seol SH, Kim DI, Cho KI, et al: A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology. 122:133–143. 2012.PubMed/NCBI View Article : Google Scholar
15	Hashimoto A, Miyakoda G, Hirose Y and Mori T: Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis. 189:350–357. 2006.PubMed/NCBI View Article : Google Scholar
16	Ito H, Hashimoto A, Matsumoto Y, Yao H and Miyakoda G: Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. J Cereb Blood Flow Metab. 30:343–351. 2010.PubMed/NCBI View Article : Google Scholar
17	Bai Y, Muqier Murakami H, Iwasa M, Sumi S, Yamada Y, Ushikoshi H, Aoyama T, Nishigaki K, Takemura G, et al: Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. Clin Exp Pharmacol Physiol. 38:658–665. 2011.PubMed/NCBI View Article : Google Scholar
18	Pelletier S, Dubé J, Villeneuve A, Gobeil F Jr, Bernier SG, Battistini B, Guillemette G and Sirois P: Adenosine induces cyclic-AMP formation and inhibits endothelin-1 production/secretion in guinea-pig tracheal epithelial cells through A(2B) adenosine receptors. Br J Pharmacol. 129:243–250. 2000.PubMed/NCBI View Article : Google Scholar
19	Shima A, Maki T, Mimura N, Yamashita H, Emoto N, Yoshifuji H and Takahashi R: A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus. eNeurologicalSci. 24(100351)2021.PubMed/NCBI View Article : Google Scholar
20	Armstead WM, Bohman LE, Riley J, Yarovoi S, Higazi AA and Cines DB: tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1. J Neurotrauma. 30:1898–1907. 2013.PubMed/NCBI View Article : Google Scholar
21	Jiang Y, Zeng Y, Huang X, Qin Y, Luo W, Xiang S, Sooranna SR and Pinhu L: Nur77 attenuates endothelin-1 expression via downregulation of NF-κB and p38 MAPK in A549 cells and in an ARDS rat model. Am J Physiol Lung Cell Mol Physiol. 311:L1023–Ll035. 2016.PubMed/NCBI View Article : Google Scholar
22	Solone X, Wells B and Chrestensen C: MAP kinases mediate regulation of eNOS through phosphorylation of different sites. Biochem Mol Biol. 33(S1)(478.10)2019.
23	Lee KM, Lee HJ, Kim MK, Kim HS, Jung GS, Hur SH, Kim HT, Cho WH, Kim JG, Kim BW, et al: Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. Atherosclerosis. 207:391–398. 2009.PubMed/NCBI View Article : Google Scholar
24	Lim JH, Woo JS and Shin YW: Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways. Korean J Intern Med. 24:113–122. 2009.PubMed/NCBI View Article : Google Scholar
25	Chao TH, Tseng SY, Li YH, Liu PY, Cho CL, Shi GY, Wu HL and Chen JH: A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clin Sci (Lond). 123:147–159. 2012.PubMed/NCBI View Article : Google Scholar
26	Medina-Leyte DJ, Domínguez-Pérez M, Mercado I, Villarreal-Molina MT and Jacobo-Albavera L: Use of human umbilical vein endothelial cells (HUVEC) as a model to study cardiovascular disease: A review. Appl Sci. 10(938)2020.
27	Xiong T, Zhang Z, Zheng R, Huang J and Guo L: N-acetyl cysteine inhibits lipopolysaccharide-induced apoptosis of human umbilical vein endothelial cells via the p38MAPK signaling pathway. Mol Med Rep. 20:2945–2953. 2019.PubMed/NCBI View Article : Google Scholar
28	Cho HY, Park CM, Kim MJ, Chinzorig R, Cho CW and Song YS: Comparative effect of genistein and daidzein on the expression of MCP-1, eNOS, and cell adhesion molecules in TNF-α-stimulated HUVECs. Nutr Res Pract. 5:381–388. 2011.PubMed/NCBI View Article : Google Scholar
29	Kong LJ, Liu XQ, Xue Y, Gao W and Lv QZ: Muramyl dipeptide induces reactive oxygen species generation through the NOD2/COX-2/NOX4 signaling pathway in human umbilical vein endothelial cells. J Cardiovasc Pharmacol. 71:352–358. 2018.PubMed/NCBI View Article : Google Scholar
30	Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR and Quyyumi AA: Prognostic value of coronary vascular endothelial dysfunction. Circulation. 106:653–658. 2002.PubMed/NCBI View Article : Google Scholar
31	Widlansky ME, Gokce N, Keaney JF Jr and Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 42:1149–1160. 2003.PubMed/NCBI View Article : Google Scholar
32	Bonetti PO, Lerman LO and Lerman A: Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 23:168–175. 2003.PubMed/NCBI View Article : Google Scholar
33	Chua BH, Chua CC, Diglio CA and Siu BB: Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1178:201–206. 1993.PubMed/NCBI View Article : Google Scholar
34	Madden JA: Role of the vascular endothelium and plaque in acute ischemic stroke. Neurology. 79 (Suppl 1):S58–S62. 2012.PubMed/NCBI View Article : Google Scholar
35	Goto S: Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler. (Suppl 6):3–11. 2005.PubMed/NCBI View Article : Google Scholar
36	Kim KY, Shin HK, Choi JM and Hong KW: Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther. 300:709–715. 2002.PubMed/NCBI View Article : Google Scholar
37	Kawanabe Y, Takahashi M, Jin X, Abdul-Majeed S, Nauli AM, Sari Y and Nauli SM: Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation. PLoS One. 7(e44476)2012.PubMed/NCBI View Article : Google Scholar
38	Hohlfeld T, Klemm P, Thiemermann C, Warner TD, Schrör K and Vane JR: The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol. 116:3309–3315. 1995.PubMed/NCBI View Article : Google Scholar
39	Zhang H, Park Y, Wu J, Chen Xp, Lee S, Yang J, Dellsperger KC and Zhang C: Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 116:219–230. 2009.PubMed/NCBI View Article : Google Scholar